Peter A. Thompson - 02 Jun 2021 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: PMVP
Reported as of: 02 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2021, 17:41:40 UTC
Next SEC filing: 21 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Winston Kung, by power of attorney

Key filing fact

Peter A. Thompson filed Form 4 for PMV Pharmaceuticals, Inc. (PMVP) on 09 Jun 2021.

Key facts

This page summarizes Peter A. Thompson's Form 4 filing for PMV Pharmaceuticals, Inc. (PMVP).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2021, 17:41.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PMVP transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +16,333
Change %
Price: $0.000000
Shares after: 16,333
Date: 02 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,333
Exercise price: $32.29
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares subject to the option vest on the earlier of (i) June 2, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP V LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP.